slowing the disease's march, not curing it
For the first time in Brazil's medical history, a treatment exists that does not merely soften the symptoms of Alzheimer's disease but slows the disease itself — a distinction that carries profound weight for the more than one million Brazilians living with this condition and the families who accompany them through its long unraveling. On December 22, 2025, Brazil's health regulator Anvisa approved Leqembi, a monoclonal antibody that clears the toxic beta-amyloid proteins at the biological root of Alzheimer's, aligning Brazil with international standards already established in the United States. The approval marks a turning point in how medicine confronts one of humanity's most feared forms of cognitive loss — not with resignation, but with a genuine, if still incomplete, intervention.
- Over one million Brazilians with Alzheimer's have lived without access to any treatment capable of altering the disease's course — until now.
- Leqembi works by enlisting the immune system to clear beta-amyloid plaques from the brain, targeting the root cause rather than masking its effects.
- An 18-month clinical trial of nearly 1,800 patients, published in the New England Journal of Medicine, demonstrated meaningful slowing of cognitive and functional decline — not a cure, but a measurable difference.
- Brazilian neurosurgeons and specialists welcome the approval with measured optimism, cautioning that high costs and the absence of long-term safety data demand continued scrutiny.
- Brazil's approval follows the FDA's 2023 authorization, bringing the country into step with global standards and opening a door that had remained closed to its patients.
On December 22, 2025, Brazil's health regulator Anvisa approved Leqembi — a drug whose active ingredient, lecanemab, does something Brazilian medicine has never before been able to offer Alzheimer's patients: slow the actual progression of the disease. Administered by intravenous infusion every two weeks, it targets beta-amyloid proteins that accumulate in the brain and destroy nerve cells, using the body's own immune system to clear them away.
For decades, treatment meant symptom management — vitamins, memory stimulants, blood vessel dilators — none of which touched what was happening inside the brain. Researchers eventually identified tau and beta-amyloid proteins as the central culprits, and Leqembi emerged as the first therapy to act directly on one of them. The clinical evidence came from a trial of nearly 1,800 early-stage patients over eighteen months, published in the New England Journal of Medicine in 2022, showing meaningful slowing of cognitive and functional decline compared to placebo.
The Brazilian medical community has responded with cautious optimism. Neurosurgeon Helder Picarelli of the Hospital das Clínicas at the University of São Paulo acknowledges the drug's promise while urging patience — the long-term cost-benefit picture remains incomplete, and the therapy carries a significant price tag. Leqembi has been in use in the United States since the FDA approved it in 2023, and Brazil's authorization now brings the country into alignment with those international standards. What remains open is how broadly accessible the treatment will become, and whether time will confirm what the early data suggests.
On December 22, 2025, Brazil's health regulator Anvisa gave the green light to Leqembi, a drug that does something the country's medical system has never been able to do before: slow the actual progression of Alzheimer's disease rather than merely manage its symptoms. The medication, whose active ingredient is lecanemab, is designed for people in the early stages of dementia caused by Alzheimer's, and it works by targeting the biological root of the condition itself—the accumulation of beta-amyloid proteins that clump together in the brain and poison nerve cells.
For decades, treating Alzheimer's meant offering patients and their families little more than symptom relief. Doctors could prescribe vitamins, memory stimulants, and blood vessel dilators, but none of these addressed what was actually happening inside the brain. The disease would progress regardless. That changed as researchers gradually pieced together the molecular mechanics of Alzheimer's, understanding that two proteins—tau and beta-amyloid—were the culprits. Leqembi targets the beta-amyloid specifically, using the body's own immune system to clear away these toxic deposits. The drug is administered through intravenous infusion, typically in a clinical setting, every two weeks.
The evidence supporting Leqembi's approval came from a substantial clinical trial published in the New England Journal of Medicine in 2022. Nearly 1,800 patients with early-stage Alzheimer's received the drug or a placebo over eighteen months. The results showed that lecanemab meaningfully slowed cognitive and functional decline compared to the control group—not a cure, but a genuine slowing of the disease's march. This distinction matters enormously to the more than one million Brazilians currently living with Alzheimer's, and to their families.
The medical community in Brazil has received the news with cautious optimism. Helder Picarelli, a neurosurgeon at the Hospital das Clínicas at the University of São Paulo's medical school, acknowledges the drug's promise but urges patience. He points out that more time and observation are needed to fully understand the long-term cost-benefit equation, especially given the high price tag attached to this kind of cutting-edge therapy and the sheer complexity of the disease itself.
Leqembi is not new to the world. The FDA approved it in the United States in 2023, and it has been in use there since then. Brazil's approval now brings the country into alignment with international standards for Alzheimer's treatment, giving Brazilian patients access to a disease-modifying therapy that was previously unavailable to them. The drug represents a genuine shift in how medicine approaches one of the most devastating neurodegenerative conditions—from managing decline to actively slowing it. What remains to be seen is how widely accessible it will become, and whether the long-term data will confirm what the early trials suggest.
Notable Quotes
More data and long-term observations are necessary to reach a definitive conclusion about the cost-benefit ratio and long-term impact, given the disease's complexity and the high cost of new therapies.— Helder Picarelli, neurosurgeon at Hospital das Clínicas, USP
The Hearth Conversation Another angle on the story
Why does it matter that this drug targets the disease itself rather than just the symptoms?
Because for the first time, we're not just making someone more comfortable while the disease destroys their brain. We're actually slowing the destruction. That's a fundamentally different kind of medicine.
But the source mentions the drug is expensive and requires ongoing infusions. Who actually gets to use it?
That's the real question no one's answered yet. The approval is one thing. Access is another. In Brazil, that depends on whether the health system will cover it, whether patients can afford it, and whether there are enough clinics equipped to give the infusions.
The trial involved 1,795 people. Is that a lot?
For a disease this complex, yes. But it's also a relatively small window into how a drug will behave in millions of real people over decades. That's why Picarelli is right to ask for more time.
What does "early-stage Alzheimer's" actually mean? Can people in later stages use it?
Early stage means mild dementia—the person knows something is wrong, they're losing words and forgetting appointments, but they're not yet unable to care for themselves. Once the disease progresses further, the drug apparently doesn't work. So timing matters enormously.
If this drug has been available in the US since 2023, why did Brazil take so long?
Regulatory processes move at different speeds in different countries. The FDA and Anvisa have different standards, different data requirements, different timelines. Brazil wasn't slow—it was thorough.
What happens to the million Brazilians with Alzheimer's who are already in later stages?
They're still waiting. This drug doesn't help them. The real challenge now is catching people early enough to use it, and making sure they can actually get it.